These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 27998963)

  • 1. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine.
    Batth IS; Mitra A; Manier S; Ghobrial IM; Menter D; Kopetz S; Li S
    Ann Oncol; 2017 Mar; 28(3):468-477. PubMed ID: 27998963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
    Chen X; Wang L; Lou J
    Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid biopsies.
    Lianidou E; Pantel K
    Genes Chromosomes Cancer; 2019 Apr; 58(4):219-232. PubMed ID: 30382599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
    Fici P
    Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.
    Gold B; Cankovic M; Furtado LV; Meier F; Gocke CD
    J Mol Diagn; 2015 May; 17(3):209-24. PubMed ID: 25908243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid biopsy: novel technologies and clinical applications.
    Reimers N; Pantel K
    Clin Chem Lab Med; 2019 Feb; 57(3):312-316. PubMed ID: 30465714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The current status of the clinical utility of liquid biopsies in cancer.
    Snow A; Chen D; Lang JE
    Expert Rev Mol Diagn; 2019 Nov; 19(11):1031-1041. PubMed ID: 31482746
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic profiling of cancer with circulating tumor DNA analysis.
    Lu L; Bi J; Bao L
    J Genet Genomics; 2018 Feb; 45(2):79-85. PubMed ID: 29502957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
    Di Meo A; Bartlett J; Cheng Y; Pasic MD; Yousef GM
    Mol Cancer; 2017 Apr; 16(1):80. PubMed ID: 28410618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
    Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
    Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the Cancer Genome in Blood.
    Dawson SJ
    Cold Spring Harb Perspect Med; 2019 Apr; 9(4):. PubMed ID: 29844219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA.
    Junqueira-Neto S; Batista IA; Costa JL; Melo SA
    Acta Cytol; 2019; 63(6):479-488. PubMed ID: 30783027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The feasibility of using mutation detection in ctDNA to assess tumor dynamics.
    Yi X; Ma J; Guan Y; Chen R; Yang L; Xia X
    Int J Cancer; 2017 Jun; 140(12):2642-2647. PubMed ID: 28124376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilizing circulating tumour DNA in radiation oncology.
    Rostami A; Bratman SV
    Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced liquid biopsy technologies for circulating biomarker detection.
    Soda N; Rehm BHA; Sonar P; Nguyen NT; Shiddiky MJA
    J Mater Chem B; 2019 Nov; 7(43):6670-6704. PubMed ID: 31646316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
    Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
    CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid biopsy in prostate cancer: A novel dual biomarker analysis approach integrating circulating tumor cells and circulating tumor DNA data.
    Li Q; Tang L; Zhao Y; Li Z; Ma W; Ma L
    Cell Mol Biol (Noisy-le-grand); 2024 Sep; 70(8):158-163. PubMed ID: 39262247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid biopsy: Circulating exosomal long noncoding RNAs in cancer.
    Jiang N; Pan J; Fang S; Zhou C; Han Y; Chen J; Meng X; Jin X; Gong Z
    Clin Chim Acta; 2019 Aug; 495():331-337. PubMed ID: 31054913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.